Want to see BVS full AI Analyst Report?
Top Page
Bioventus
(NASDAQ:BVS)
Select Model
Select Model
Rating:71Outperform
Price Target:
$17.00
▲(44.07% Upside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by improving financial performance (profitability rebound, strong free-cash-flow conversion, and declining debt) and supportive technical trend strength (price well above key moving averages). This is balanced by a relatively expensive valuation (P/E ~31 with no dividend yield provided) and near-term momentum being overbought (RSI ~79), while the earnings call was constructive with reaffirmed guidance and deleveraging progress but included added uncertainty from the strategic review.
Positive Factors
Free cash flow conversion
Bioventus converts reported earnings into cash effectively: operating cash flow rose to ~$105.8M TTM and free cash flow tracked net income at ~0.98x. Durable cash conversion strengthens liquidity, funds organic investment, supports deleveraging and reduces refinancing risk over the medium term.
Negative Factors
Uneven revenue history and visibility
Revenue growth has been inconsistent: annual revenue was essentially flat in 2025 and prior years included sharp profitability drawdowns. That uneven top‑line history reduces medium‑term visibility and raises execution risk for sustaining margins and cash generation through cyclical or competitive pressures.
Read all positive and negative factors
Positive Factors
Negative Factors
Free cash flow conversion
Bioventus converts reported earnings into cash effectively: operating cash flow rose to ~$105.8M TTM and free cash flow tracked net income at ~0.98x. Durable cash conversion strengthens liquidity, funds organic investment, supports deleveraging and reduces refinancing risk over the medium term.
Read all positive factors
Bioventus Key Performance Indicators (KPIs)
Any
Revenue by Segment
Analyzes revenue from different business segments, highlighting which areas are driving growth and which may need strategic adjustments to improve performance.
Analyzes revenue from different business segments, highlighting which areas are driving growth and which may need strategic adjustments to improve performance.
Data provided by:
The Fly
The FlyBioventus (BVS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.20B
Dividend YieldN/A
Average Volume (3M)654.88K
Price to Earnings (P/E)18.3
Beta (1Y)0.74
Revenue Growth3.14%
EPS GrowthN/A
CountryUS
Employees950
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.80
Shares Outstanding68,305,145
10 Day Avg. Volume553,877
30 Day Avg. Volume654,875
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.69
Price to Sales (P/S)0.87
P/FCF Ratio6.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.33Price Target Upside55.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.78
Revenue Forecast (FY)$605.04M
Bioventus Business Overview & Revenue Model
Company Description
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular...
How the Company Makes Money
Bioventus makes money primarily by selling musculoskeletal medical products to healthcare providers and healthcare facilities (and, for certain products, through channels that support patient access). Its revenue is generated from commercializing ...
Bioventus Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call conveyed predominantly positive operational and financial momentum: solid top-line growth (+4% company-wide; +12% in Pain Treatments), margin expansion, strong cash generation and meaningful deleveraging, plus accelerating evidence of traction in strategic growth drivers (PRP, PNS, Ultrasonics, International). Near-term headwinds are mostly transitory and include timing-related revenue shifts (~$2M), modest declines in Surgical, Restorative and International segments, a ~90 bp gross margin drag, higher operating investment and an elevated effective tax rate. Management reaffirmed full-year guidance and expects H2 revenue and cash-flow acceleration, but the announced strategic review introduces a degree of uncertainty. Overall, the positives (durable revenue drivers, profitability, cash generation, deleveraging and confirmed guidance) outweigh the contained near-term challenges.Positive Updates
Overall Financial Performance
Q2 revenue $153M, up 4% YoY; adjusted EBITDA $35M, up >$1M YoY with margin of 23% (expanded 20 bps YoY); adjusted EPS $0.22 vs $0.21 prior year; year-to-date adjusted EPS up 24%.
Negative Updates
Surgical Solutions Decline and Timing Shift
Surgical Solutions revenue $50M, down 5% YoY (but up 5% sequentially). Performance impacted by timing of Ultrasonics capital placements and international orders that shifted approximately $2M of revenue into H2, creating a notable near-term headwind for the segment.
Read all updates
Q2-2026 Updates
Positive
Negative
Overall Financial Performance
Q2 revenue $153M, up 4% YoY; adjusted EBITDA $35M, up >$1M YoY with margin of 23% (expanded 20 bps YoY); adjusted EPS $0.22 vs $0.21 prior year; year-to-date adjusted EPS up 24%.
Read all positive updates
Company Guidance
Bioventus reaffirmed full-year 2026 guidance calling for revenue of $600–610 million, adjusted EPS of $0.75–0.79 per diluted share, cash from operations of $84–89 million and a full‑year adjusted EBITDA margin of at least 20%. The company pointed to Q2 results that support this outlook: revenue of $153 million (+4% YoY), adjusted EBITDA of $35 million (23% margin, +20 bps YoY), adjusted EPS of $0.22, cash from operations of $20 million and adjusted gross margin of 75% (‑90 bps YoY). Year‑to‑date metrics include 5% revenue growth, 12% adjusted EBITDA growth, 24% adjusted EPS growth and $22 million improvement in cash from operations; Bioventus ended the quarter with $29 million cash, $248 million debt, repaid $24 million in the quarter ($46 million YTD), reduced net leverage to below 2x with a path to under 1.5x by year‑end. Management also expects year‑over‑year revenue growth to accelerate in the second half by over 300 basis points (half from Surgical Solutions timing/acceleration and half from PNS/PRP) and for cash from operations to approximately double in H2 versus H1.Bioventus Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
63
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 581.85M | 568.09M | 573.28M | 512.35M | 512.12M | 430.90M |
| Gross Profit | 395.64M | 382.43M | 388.23M | 328.19M | 331.08M | 302.71M |
| EBITDA | 92.82M | 99.21M | 39.22M | -23.07M | -121.61M | 45.48M |
| Net Income | 54.46M | 22.73M | -33.54M | -156.23M | -158.70M | 19.38M |
Balance Sheet | ||||||
| Total Assets | 673.35M | 683.56M | 727.96M | 810.91M | 1.37B | 1.23B |
| Cash, Cash Equivalents and Short-Term Investments | 29.46M | 51.24M | 41.58M | 36.96M | 30.19M | 43.93M |
| Total Debt | 263.75M | 311.35M | 335.63M | 394.85M | 418.07M | 357.68M |
| Total Liabilities | 395.93M | 455.11M | 542.35M | 589.79M | 960.43M | 692.07M |
| Stockholders Equity | 228.31M | 184.10M | 147.94M | 173.59M | 325.24M | 458.92M |
Cash Flow | ||||||
| Free Cash Flow | 94.29M | 71.41M | 37.79M | 7.98M | -15.02M | 2.10M |
| Operating Cash Flow | 96.87M | 73.98M | 38.80M | 15.34M | -13.54M | 22.99M |
| Investing Cash Flow | -4.09M | -3.25M | 22.96M | 15.81M | -116.44M | -283.76M |
| Financing Cash Flow | -95.00M | -61.44M | -54.58M | -26.65M | 62.08M | 273.37M |
Bioventus Technical Analysis
Positive
11.80
Price Trends
11.65
Positive
10.65
Positive
9.30
Positive
Market Momentum
0.74
Positive
65.92
Neutral
58.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BVS, the sentiment is Positive. The current price of 11.8 is below the 20-day moving average (MA) of 13.57, above the 50-day MA of 11.65, and above the 200-day MA of 9.30, indicating a bullish trend. The MACD of 0.74 indicates Positive momentum. The RSI at 65.92 is Neutral, neither overbought nor oversold. The STOCH value of 58.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BVS.
Bioventus Risk Analysis
Bioventus disclosed 81 risk factors in its most recent earnings report. Bioventus reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioventus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.20B | 18.27 | 28.39% | ― | 3.14% | ― | |
64 Neutral | $665.80M | -15.77 | -11.53% | ― | 14.49% | 6.68% | |
59 Neutral | $778.06M | 35.16 | 4.60% | ― | 5.31% | ― | |
58 Neutral | $857.83M | -58.59 | -8.23% | ― | 15.30% | 40.66% | |
55 Neutral | $416.29M | -6.83 | -14.05% | ― | 2.99% | 51.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
BVS
Bioventus
14.68
7.60
107.34%
OFIX
Orthofix Medical
10.48
-4.07
-27.97%
VREX
Varex Imaging
18.46
7.12
62.79%
KIDS
OrthoPediatrics
26.50
7.35
38.38%
SIBN
SI-Bone
19.91
4.27
27.30%
Bioventus Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Bioventus Reports Solid Q2 Results Amid Strategic Review
Positive
Aug 5, 2026
On August 5, 2026, Bioventus reported second-quarter 2026 results showing worldwide revenue up 4% to $153.2 million, driven by double-digit growth in Pain Treatments, and net income rising to $33.4 million from $7.5 million a year earlier, aided b...
Executive/Board ChangesShareholder Meetings
Bioventus Shareholders Back Directors and Auditor at 2026 Meeting
Positive
Jun 4, 2026
Bioventus, Inc. held its 2026 Annual Meeting of Stockholders on June 3, 2026, with approximately 90.23% of outstanding common shares represented in person or by proxy. Shareholders elected 12 directors, including William A. Hawkins, John A. Bartho...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Bioventus Affirms Outlook After FDA Device Reclassification
Neutral
May 21, 2026
On April 16, 2026, the U.S. Food and Drug Administration reclassified non-invasive bone growth stimulators, including Bioventus’ Exogen Ultrasound Bone Healing System, from Class III to Class II devices, while the Centers for Medicare Medic...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.